跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ABIRANAT TABLETS 250MG USP - HSA Drug Approval Details
Approvals
/
HSA
/
ABIRANAT TABLETS 250MG USP
Approved
THERAPEUTIC
ABIRANAT TABLETS 250MG USP
NATCO PHARMA (PHARMA - DIVISION) LIMITED (UNIT V) - INDIANATCO PHARMA (PHARMA - DIVISION) LIMITED (UNIT XII) (INDIA)
🇸🇬 Health Sciences Authority
Approval Date
Oct 18, 2019
Approval ID
f496a1060e0d706c
Company
NATCO PHARMA (PHARMA - DIVISION) LIMITED (UNIT V) - INDIANATCO PHARMA (PHARMA - DIVISION) LIMITED (UNIT XII) (INDIA)
Type
Therapeutic
Approval Details
Approval Id
f496a1060e0d706c
Drug Name
ABIRANAT TABLETS 250MG USP
Product Name
ABIRANAT TABLETS 250MG USP
Approval Number
SIN15833P
Approval Date
2019-10-18
Registrant
NATCO PHARMA ASIA PTE. LTD.
Licence Holder
NATCO PHARMA ASIA PTE. LTD.
Drug Type
Therapeutic
Forensic Classification
PRESCRIPTION ONLY MEDICINES
Dosage Form
TABLET
Route Of Administration
ORAL
Atc Code
L02BX03
Atc Item Name
abiraterone
Pharma Manufacturer Name
NATCO PHARMA ASIA PTE. LTD.
Active Ingredients
Abiraterone Acetate
250 mg
ABIRATERONE ACETATE
250 MG
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
Oct 18, 2019
Approval ID
f496a1060e0d706c
Type
Therapeutic
Back to HSA Approvals